2023
DOI: 10.1016/j.jaut.2022.102982
|View full text |Cite
|
Sign up to set email alerts
|

Non-coding RNAs in immunoregulation and autoimmunity: Technological advances and critical limitations

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
5
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 10 publications
(5 citation statements)
references
References 374 publications
0
5
0
Order By: Relevance
“…However, the application of circRNAs in clinical settings still requires further research, including how to construct more efficient and specific carriers for the delivery of circRNAs to specific cells or tissues. Additionally, it is important to clarify circRNAs’ pharmacokinetics, biodistribution in the body, and adverse reactions ( 116 ).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…However, the application of circRNAs in clinical settings still requires further research, including how to construct more efficient and specific carriers for the delivery of circRNAs to specific cells or tissues. Additionally, it is important to clarify circRNAs’ pharmacokinetics, biodistribution in the body, and adverse reactions ( 116 ).…”
Section: Discussionmentioning
confidence: 99%
“…Evidently, non-coding RNAs (ncRNAs) can effectively modulate the proliferation, migration, and invasion capacities of RA-FLSs through various pathways and targets, thus contributing to the reduction of irreversible damage to joint cartilage and bone ( 167 ). Moreover, drugs specifically tailored to target the biological functions of RA-FLS can be locally administered, enabling higher drug concentrations and prolonged therapeutic durations, which enhances treatment efficacy while reducing systemic drug distribution, thereby minimizing adverse effects on other tissues and organs ( 116 , 171 ). This comprehensive therapeutic strategy represents a promising avenue for RA management.…”
Section: Discussionmentioning
confidence: 99%
“…Some of these papers barely mentioned circRNA, 64,[86][87][88][89][90][91][92] while others focused on other types of ncRNAs such as miRNA and LncRNA. 93,94 A few papers discussed the role of circRNA in other types of diseases but did not mention MS. [95][96][97][98] The lack of comprehensive discussion on the role of circRNA in MS and other diseases may be attributed to the limited understanding of this molecule. Further research is needed to fully elucidate the functions of circRNA in health and disease, particularly in the context of complex diseases such as MS.…”
Section: Discussionmentioning
confidence: 99%
“…The expression profiles of ncRNAs vary depending on the kind of cell, the stage of development, and the physiological conditions to which the cells are exposed ( 52 ). This holds true even for immune system cells; fluctuations in the expression levels of ncRNAs in immune cells have been observed in various conditions, such as cancer, inflammation, and autoimmune diseases ( 53 , 54 ). ncRNAs are regulators of immune system function because of their ability to alter gene expression in immune cells.…”
Section: Methodsmentioning
confidence: 99%